Switzerland's Lonza Group AG has emerged as a potential friendly suitor for Canadian drug maker Patheon Inc. with a $458.5-million (U.S.) bid Patheon says trumps a hostile takeover offer from JLL Partners Inc. Lonza Group is offering $3.55 per share for Patheon, well above the $2 per share offered by JLL, a New York-based investment firm. "Our interest in Patheon is consistent with Lonza's stated strategy of expanding our offering across the pharmaceutical manufacturing value chain," Lonza chief executive officer Stefan Borgas said. Patheon's board of directors has put its support behind the Lonza bid after rejecting JLL's offer as inadequate. PTI (TSX) rose 80 cents to $3.38.
© The Globe and Mail
Only GlobeinvestorGOLD combines the strength of powerful investing tools with the insight of The Globe and Mail.
Discover a wealth of investment information and and exclusive features.
